Search Results
Your search for The ASCO P matches 3781 pages
Showing 3701 - 3750Delaying Androgen Deprivation Therapy May Be Safe for Men With Prostate Cancer Relapse Detected by PSA Testing
According to a large, population-based observational study of men who had a prostate-specific antigen (PSA)-only based relapse after prostate surgery or radiation therapy, delaying androgen deprivation therapy until the onset of symptoms or appearance of cancer on a scan does not substantially...
ASCO Releases Companion Guideline on Disease Management for Patients With Advanced HER2-Positive Breast Cancer and Brain Metastases
As many as half of patients with metastatic HER2-positive breast cancer develop brain metastases over time. The American Society of Clinical Oncology recently released a clinical practice guideline on disease management for patients with advanced HER2-positive breast cancer and brain metastases. A...
ASCO Releases Clinical Practice Guideline on Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer
Approximately 15% of patients with breast cancer have tumors that overexpress the HER2 protein, and these patients can benefit from HER2-targeted therapies. The American Society of Clinical Oncology recently released a clinical practice guideline on systemic therapy for patients with advanced...
FDA Approves Siltuximab for Rare Castleman’s Disease
The U.S. Food and Drug Administration (FDA) today approved siltuximab (Sylvant injection) for the treatment of patients with multicentric Castleman’s disease who are human immunodeficiency virus (HIV)-negative and human herpes virus-8 (HHV-8)-negative. Multicentric Castleman’s...
FDA Approves Ramucirumab for Stomach Cancer
The U.S. Food and Drug Administration (FDA) has approved ramucirumab (Cyramza) to treat patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy....
FDA Approves Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) today approved ofatumumab (Arzerra) injection in combination with chlorambucil (Leukeran) for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate. Trial...
Perioperative Chemotherapy for High-Risk Bladder Cancer Improves Survival but Is Not Routinely Administered
A recent study published in Cancer found that, contrary to treatment guidelines for high-risk bladder cancer, neoadjuvant chemotherapy is not commonly used in routine clinical practice. Utilization of adjuvant chemotherapy was found to be increasing over time and was associated with a substantial...
Study Examines Protein Expression Biomarkers in HPV-Negative Squamous Cell Carcinomas of the Head and Neck
A quartet of proteins that play critical roles in cell replication, cell death, and DNA repair could lead to better targets for therapy against treatment-resistant head and neck squamous cell cancers. In a study presented this week at the American Association for Cancer Research (AACR) Annual...
Older People With Faster Decline in Memory and Thinking Skills May Have Lower Risk of Cancer Death
Older people who are starting to have memory and thinking problems, but do not yet have dementia, may have a lower risk of dying from cancer than people who have no memory and thinking problems, according to a study by Benito-León et al published online in Neurology. “Studies have...
Certain Genetic Variants May Help Identify Patients at Increased Risk of Bladder Cancer Recurrence
A new study by Andrew et al published in BJU International suggests that certain inherited DNA sequences may affect the prognosis of patients with bladder cancer. The findings may help physicians identify subgroups of patients with high-risk bladder cancer who should receive more frequent...
Erlotinib and Gefitinib Offer Similar Benefit in EGFR-Mutated Non–Small Cell Lung Cancer
A retrospective study has shown that two targeted therapy drugs—erlotinib (Tarceva) and gefitinib (Iressa)—achieved similar outcomes among people with metastatic or recurrent non–small cell lung cancer (NSCLC) harboring an EGFR mutation. These EGFR tyrosine kinase inhibitors have...
Satisfaction With Work-Life Balance Among U.S. Oncologists Lower Than Other Medical Specialties, Survey Says
The American Society of Clinical Oncology (ASCO) conducted a survey of U.S. oncologists between October 2012 and March 2013, evaluating satisfaction with work-life balance and career plans. The findings, reported in the Journal of Clinical Oncology by Shanafelt et al, indicate that most are...
Oropharyngeal Cancer Patients Report Benefit in Salivary Function With Reduction of Radiation Dose to Bilateral Submandibular Lymph Nodes
For head and neck cancer patients undergoing radiation therapy, a reduction in the amount of radiation treatment volume to the submandibular (level IB) lymph nodes resulted in better patient-reported salivary function, according to research presented today at the 2014 Multidisciplinary Head and...
Patients With Oropharyngeal Cancer Report Decreased Quality of Voice and Speech After Treatment
Patients with oropharyngeal cancer treated with combined chemotherapy and radiation therapy reported a decrease in their voice and speech quality for up to 1 year after the completion of treatment, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium....
Distant Metastases Occur Later and in More Subsites in Patients With HPV-Positive Squamous Cell Carcinoma of the Oropharynx
Patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx had a longer time to development of distant metastasis after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented...
HPV-Positive Oropharyngeal Cancer Associated With Higher Overall Survival Rate After Progression Than HPV-Negative Disease
A retrospective analysis of patients with oropharyngeal cancer with recurrence of disease after primary therapy in the Radiation Therapy Oncology Group (RTOG) studies 0129 and 0522 found that human papillomavirus (HPV)-positive patients had a higher overall survival rate than HPV-negative patients, ...
Novel Photon-Counting Technique Increases Detection Rate in Screening Mammography
As mammography screening has shifted to digital technology, a range of computed radiography and direct radiography systems have emerged. Digital mammography screening with a new photon-counting technique offers high diagnostic performance, according to a study reported by Weigel et al in Radiology. ...
ASCO Survey of Oncologists Finds High Overall Career Satisfaction, but Nearly Half Report Burnout
A survey of oncologists by Shanafelt et al has found that approximately 45% had at least one symptom of burnout, with risk being greatest among younger oncologists and those spending more hours per week devoted to direct patient care. However, overall career satisfaction remains high, especially...
Maintenance Capecitabine/Bevacizumab Delays Disease Progression in Metastatic Colorectal Cancer and Extends Survival in Subgroups
According to the final results of the phase III CAIRO3 trial by the Dutch Colorectal Cancer Group, maintenance treatment with capecitabine plus bevacizumab (Avastin) significantly delayed progression compared to observation in patients with metastatic colorectal cancer, and in a subset of patients, ...
Irinotecan Drug-Eluting Beads Improve Outcomes in Colorectal Cancer Patients With Liver Metastases
Irinotecan drug-eluting beads given simultaneously with FOLFOX (leucovorin, fluorouracil, oxaliplatin) and bevacizumab (Avastin) in patients with unresectable liver metastasis from colorectal cancer improved response rates, increased resectability and prolonged hepatic progression-free survival in...
Cetuximab Fails to Improve Survival in Nonoperable Esophageal Cancer
More data have emerged that discount the potential for benefit with epidermal growth factor receptor (EGFR) inhibitors in esophageal cancer. The latest comes from the RTOG 0436 randomized phase III trial in patients with nonoperable esophageal cancer, the results of which were presented at the 2014 ...
Immunotherapy Strategy Boosts Survival in Metastatic Pancreatic Cancer
Overall survival was improved in patients with metastatic pancreatic cancer through an innovative immunotherapy strategy in a multicenter study to be reported at the 2014 Gastrointestinal Cancers Symposium (Abstract 177). The results were announced at a press briefing prior to the meeting....
Ramucirumab Combination Improves Overall Survival After First Progression in Patients With Metastatic Gastric Cancer
In the global phase III RAINBOW trial of patients with metastatic gastric cancer, the investigational monoclonal antibody ramucirumab significantly improved both progression-free and overall survival when given as second-line therapy, investigators reported at a press briefing in advance of the...
Updated Myeloma Trial Shows Lenalidomide Maintenance Post-Transplant Improves Progression-Free But Not Overall Survival
A new analysis of the multiple myeloma IFM 2005-02 trial showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival. This is possibly attributed to the shorter survival time after first disease...
FDA Grants Regular Approval to Crizotinib for ALK-Positive NSCLC
The U.S. Food and Drug Administration (FDA) today granted regular approval for crizotinib (Xalkori) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Today’s...
Pemetrexed Improves Progression-Free Survival vs Gefitinib in Second-Line Setting for EGFR Wild-Type Nonsquamous NSCLC
Both pemetrexed (Alimta) and gefitinib (Iressa) are standard second-line treatments for advanced nonsquamous non–small cell lung cancer (NSCLC) in East Asia. In a phase II trial (CTONG 0806) reported at the International Association for the Study of Lung Cancer’s 15th World Conference...
Simple Blood Test May Diagnose Lung and Other Cancers
A simple blood test that measures serum free fatty acids and their metabolites may detect early-stage lung cancer and its recurrence, according to a study from The Cleveland Clinic presented at the ANESTHESIOLOGY™ 2013 Annual Meeting in San Francisco (Abstract A4267). The study was presented ...
Gemcitabine Improves Overall Survival Following Surgery for Pancreatic Cancer
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in published in the October 9 issue of...
Ramucirumab Prolongs Survival in Advanced Gastric Cancer
An investigational targeted drug that reduces blood flow to tumors prolonged the survival of patients with advanced stomach cancer after standard treatments failed, according to results of large multicenter clinical trial reported by Charles S. Fuchs, MD, MPH, of Dana-Farber Cancer Institute, and...
Treatment With Losartan May Improve Delivery of Chemotherapy Drugs in Tumors
Use of existing, well-established hypertension drugs could improve the outcome of cancer chemotherapy by opening up collapsed blood vessels in solid tumors. In a report published in Nature Communications, investigators from Massachusetts General Hospital (MGH) described how the angiotensin...
ECC 2013: Strong Showing for Ado-Trastuzumab Emtansine in Heavily Pretreated Advanced HER2-Positive Breast Cancer
Results of the phase III TH3RESA trial show that the antibody-conjugate ado-trastuzumab (Kadcyla, previously known as T-DM1) extends progression-free survival in women with advanced HER2-positive breast cancer that progressed on two or more previous HER2-directed therapies including trastuzumab...
ASTRO: Protecting Hippocampus During Whole-Brain Radiation Substantially Reduces Rate of Memory Loss in Cancer Patients
Protecting the stem cells that reside in and around the hippocampus substantially reduces the rate of cancer patients' memory loss during whole-brain radiotherapy without a significant risk of recurrence in that area of the brain, a new study shows. Results of the phase II clinical trial of...
ASTRO: Cisplatin Plus Radiation Therapy for Advanced Cervical Cancer Improves Disease-Free Survival vs Radiotherapy Alone
Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy and high–dose rate brachytherapy for stage IIIB cervical cancer is beneficial, according to research presented on September 22, 2013, at the American Society for Radiation Oncology’s 55th Annual Meeting...
ASTRO: Long-Term Androgen Deprivation in Patients With Intermediate-Risk Prostate Cancer Does Not Improve Overall Survival
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy. Investigators concluded that there were no additional benefits when compared to short-term...
Scientists Find Possible Antidote for Tamoxifen-Induced Mental Fog
Researchers from University of Rochester Medical Center have shown scientifically what many women report anecdotally: that tamoxifen is toxic to cells of the brain and central nervous system (CNS), producing mental fogginess similar to “chemo brain.” In the study, published in the...
ODAC Recommends Accelerated Approval of Pertuzumab for HER2-Positive, Early-Stage Breast Cancer
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 13 to 0, with one abstention, in favor of recommending accelerated approval of a pertuzumab (Perjeta) regimen for neoadjuvant treatment in patients with high-risk, HER2-positive, early-stage breast...
Genomic Differences Found in Two Types of Cervical Cancer
A study by Alexi Wright, MD, MPH, and colleagues at Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston has found that two common subtypes of cervical cancer, adenocarcinoma and squamous cell carcinoma, have distinct molecular profiles. The results suggest that clinical...
Sorafenib Granted Priority Review for Differentiated Thyroid Cancer
Bayer HealthCare and Onyx Pharmaceuticals announced that the FDA has granted priority review designation to the supplemental new drug application of sorafenib (Nexavar) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. The...
Best of ASCO 2013: VeriStrat Assay May Help Select NSCLC Patients for Second-Line Therapy
VeriStrat, a serum-based protein assay, can help select which patients with non–small cell lung cancer (NSCLC) who are not known to have epidermal growth factor receptor (EGFR) mutations might benefit from an EGFR-targeted agent, according to a study described at the 2013 Best of ASCO Los...
Age-Related Variations Observed in Treatment of Melanoma
Age-related variations in the treatment of melanoma were observed in a study of melanoma and its management in the elderly compared to younger patients, according to a study by Dragos Ciocan, MD, of the Unité d’Aide Méthodologique, Hôpital Robert Debré, France, and...
Carbon Ion Radiotherapy Safe and Effective for Treating Inoperable Spinal Tumors
A new analysis has found that a type of radiation therapy called carbon ion radiotherapy can control cancer growth and prolong survival in patients with spinal tumors. The study, published online in Cancer, indicates that the treatment is a promising alternative for patients whose spinal tumors...
Noninvasive Test Optimizes Colon Cancer Screening Rates
Organized mailing campaigns could substantially increase colorectal cancer screening among uninsured patients, according to a study published online in JAMA Internal Medicine. The research also suggested that a noninvasive colorectal screening approach, such as a fecal immunochemical test, might be ...
Long-Term Calcium-Channel Blocker Use for Hypertension Associated With Higher Breast Cancer Risk
Long-term use of a calcium-channel blocker to treat hypertension is associated with higher breast cancer risk, according to a report published by JAMA Internal Medicine. The study assessed the relationships between the major classes of hypertensive agents and risk of the two most common histologic...
Decision Aids Reduce Men's Conflict about PSA Screening, but Don't Change Their Decisions
Men who decide to be screened for prostate cancer and those who forgo PSA screening stick with their decisions after receiving materials explaining the risks and benefits of the test, according to a study published in JAMA Internal Medicine. The study examined both Web-based and printed tools aimed ...
Gene Test Highly Accurate in Predicting Metastasis in Patients with Thymoma
Patients diagnosed with thymoma, a rare cancer of the thymus gland, may be able to avoid certain cancer treatments associated with severe adverse events if the results of a new test reveal they are at low risk of metastasis, according to a study published in PLOS ONE. The study, by researchers at...
Richard I. Fisher, MD, Named President and CEO of Fox Chase Cancer Center
Richard I. Fisher, MD, a leading cancer center administrator and nationally recognized hematology/oncology expert, has been appointed President and CEO of Fox Chase Cancer Center. Dr. Fisher will also hold the title of Cancer Center Director of Fox Chase, serving as the principal investigator on...
Study Reveals Best of Three Schedules of Nab-paclitaxel/Bevacizumab in Metastatic Breast Cancer
In a phase II study evaluating three dosing regimens of nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) given with bevacizumab (Avastin), weekly dosing of nab-paclitaxel resulted in the highest overall response rate and longest progression-free survival. The schedule of nab-paclitaxel given...
FDA Approves Afatinib for EGFR-mutant Late-stage Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) today approved the tyrosine kinase inhibitor afatinib (Gilotrif) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors express epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21...
Five-year Survival Data from the Phase III CLASSIC Trial Show a 34% Reduction in Gastric Cancer Mortality
For patients with advanced gastric cancer, treatment with chemotherapy after surgery can reduce the risk of cancer-related death by 34% over 5 years compared to surgery alone, researchers reported at the 15th ESMO World Congress in Gastrointestinal Cancer (Abstract 007), held July 3 to 6 in...
African Americans with Chronic Lymphocytic Leukemia Do Not Live as Long as Caucasians, Despite Equal Care
A new analysis has found that among patients with chronic lymphocytic leukemia (CLL), African Americans more commonly present with advanced disease and tend to have shorter survival times than Caucasians despite receiving the same care. The results, published early online in Cancer, suggest that...
